BE2010C031I2 - - Google Patents

Download PDF

Info

Publication number: BE2010C031I2
Authority: BE; Belgium
Prior art keywords: conjugate; meningococcal serogroup; buffer; aluminium; provides
Prior art date: 2001-06-20

Application number

BE2010C031C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-20

Filing date

2010-09-13

Publication date

2021-07-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9917070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-13 Application filed by Novartis Ag filed Critical Novartis Ag

2021-07-19 Publication of BE2010C031I2 publication Critical patent/BE2010C031I2/fr

Links

239000002671 adjuvant Substances 0.000 abstract 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
229940001007 aluminium phosphate Drugs 0.000 abstract 1
229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09F—NATURAL RESINS; FRENCH POLISH; DRYING-OILS; OIL DRYING AGENTS, i.e. SICCATIVES; TURPENTINE
- C09F1/00—Obtaining purification, or chemical modification of natural resins, e.g. oleo-resins
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09G—POLISHING COMPOSITIONS; SKI WAXES
- C09G1/00—Polishing compositions
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Formation And Processing Of Food Products (AREA)

BE2010C031C 2001-06-20 2010-09-13 BE2010C031I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0115176.0A GB0115176D0 (en)	2001-06-20	2001-06-20	Capular polysaccharide solubilisation and combination vaccines
PCT/IB2002/003191 WO2003007985A2 (fr)	2001-06-20	2002-06-20	Solubilisation de polysaccharides capsulaires et vaccins de combinaison

Publications (1)

Publication Number	Publication Date
BE2010C031I2 true BE2010C031I2 (fr)	2021-07-19

Family

ID=9917070

Family Applications (4)

Application Number	Title	Priority Date
BE2010C031C BE2010C031I2 (fr)	2001-06-20	2010-09-13
BE2010C033C BE2010C033I2 (fr)	2001-06-20	2010-09-13
BE2010C032C BE2010C032I2 (fr)	2001-06-20	2010-09-13
BE2011C001C BE2011C001I2 (fr)	2001-06-20	2011-01-13

Family Applications After (3)

Application Number	Title	Priority Date
BE2010C033C BE2010C033I2 (fr)	2001-06-20	2010-09-13
BE2010C032C BE2010C032I2 (fr)	2001-06-20	2010-09-13
BE2011C001C BE2011C001I2 (fr)	2001-06-20	2011-01-13

Country Status (23)

Country	Link
US (9)	US8753651B2 (fr)
EP (10)	EP1401489B2 (fr)
JP (4)	JP5075317B2 (fr)
CN (4)	CN100482273C (fr)
AT (3)	ATE474594T1 (fr)
AU (3)	AU2002321716B2 (fr)
BE (4)	BE2010C031I2 (fr)
BR (2)	BRPI0210590B8 (fr)
CA (3)	CA2450203C (fr)
CY (6)	CY1110820T1 (fr)
DE (6)	DE122011000003I1 (fr)
DK (6)	DK2263688T4 (fr)
ES (9)	ES2603275T3 (fr)
FR (4)	FR10C0044I1 (fr)
GB (1)	GB0115176D0 (fr)
LU (4)	LU91734I2 (fr)
MX (1)	MXPA03011462A (fr)
NL (3)	NL300458I2 (fr)
NZ (2)	NZ529881A (fr)
PT (6)	PT1401489E (fr)
RU (2)	RU2381814C2 (fr)
TR (2)	TR201808026T4 (fr)
WO (1)	WO2003007985A2 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
AP1897A (en)	2001-01-23	2008-10-10	Aventis Pasteur	Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ES2318117T3 (es) *	2002-03-26	2009-05-01	Novartis Vaccines And Diagnostics S.R.L.	Sacaridos modificados que tienen una estabilidad mejorada en agua.
GB0302218D0 (en) *	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
DE60328481D1 (de)	2002-05-14	2009-09-03	Novartis Vaccines & Diagnostic	Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
AU2003250204B8 (en) *	2002-08-02	2008-07-10	Glaxosmithkline Biologicals S.A.	Neisserial vaccine compositions comprising a combination of antigens
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
PT2353608T (pt) *	2002-10-11	2020-03-11	Novartis Vaccines And Diagnostics S R L	Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
EP1562982B1 (fr)	2002-11-15	2010-05-05	Novartis Vaccines and Diagnostics S.r.l.	Proteines de surface inattendues du neisseria meningitidis
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
US10272147B2 (en) *	2003-01-30	2019-04-30	Glaxosmithkline Biologicals S.A.	Injectable vaccines against multiple meningococcal serogroups
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
AU2004251734B2 (en) *	2003-06-23	2010-11-04	Baxalta GmbH	Vaccines against group Y neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
PT1961426E (pt) *	2003-10-02	2011-06-28	Novartis Vaccines & Diagnostic	Vacinas combinadas contra a meningite
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
GB0408977D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Meningococcal fermentation for preparing conjugate vaccines
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
PL1740217T3 (pl)	2004-04-30	2012-03-30	Novartis Ag	Szczepienie koniugatem meningokokowym
GB0409745D0 (en) *	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0410866D0 (en)	2004-05-14	2004-06-16	Chiron Srl	Haemophilius influenzae
GB0411387D0 (en)	2004-05-21	2004-06-23	Chiron Srl	Analysis of saccharide length
GB0413868D0 (en) *	2004-06-21	2004-07-21	Chiron Srl	Dimensional anlaysis of saccharide conjugates
AU2005279821A1 (en) *	2004-08-30	2006-03-09	Sanofi Pasteur, Inc.	Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
KR20070095868A (ko) *	2004-09-21	2007-10-01	사노피 파스퇴르 인크	다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) *	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) *	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
DK2351772T3 (en)	2005-02-18	2016-09-05	Glaxosmithkline Biologicals Sa	Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
US8062644B2 (en)	2005-02-18	2011-11-22	Novartis Vaccines & Diagnostics Srl.	Immunogens from uropathogenic Escherichia coli
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
EP2425856A1 (fr)	2005-04-08	2012-03-07	Wyeth LLC	Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
EP2329843A3 (fr)	2005-04-18	2011-09-14	Novartis Vaccines and Diagnostics, Inc.	Expression de l'antigène de virus de l'hépatite B pour la préparation d'un vaccin
GB0513071D0 (en) *	2005-06-27	2005-08-03	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0513069D0 (en) *	2005-06-27	2005-08-03	Glaxosmithkline Biolog Sa	Immunogenic composition
ATE536884T1 (de) *	2005-06-27	2011-12-15	Glaxosmithkline Biolog Sa	Immunogene zusammensetzung
WO2007026249A2 (fr)	2005-09-01	2007-03-08	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Vaccination multiple comprenant des meningocoques du serogroupe c
JP5047969B2 (ja) *	2005-09-05	2012-10-10	グラクソスミスクラインバイオロジカルズソシエテアノニム	髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
KR20130135399A (ko)	2006-03-17	2013-12-10	더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈	복합 다가 면역원성 콘쥬게이트의 제조 방법
EP2357001B1 (fr)	2006-03-22	2018-03-07	GlaxoSmithKline Biologicals S.A.	Schema posologique pour une immunisation avec des conjugues de meningocoques
US10828361B2 (en) *	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en)	2006-03-22	2006-05-03	Chiron Srl	Separation of conjugated and unconjugated components
TW200806315A (en) *	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN101081296B (zh) *	2006-05-29	2010-08-04	北京民海生物科技有限公司	一种b型流感嗜血杆菌荚膜多糖制备方法及其联合疫苗
US7491517B2 (en)	2006-07-19	2009-02-17	Jeeri R Reddy	Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
CA2659552A1 (fr)	2006-08-16	2008-02-21	Novartis Ag	Immunogenes pour escherichia coli uropathogene
CL2007002909A1 (es) *	2006-10-10	2008-04-18	Wyeth Corp	Metodo para reduccion o extraccion de impurezas de proteinas a partir de lisado celular de streptoccocus pneumoniae que comprende calentar dicho lisado, separar a los precipitantes a partir de dicho lisado produciendo un lisado que contiene polisacar
GB0700136D0 (en)	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
PL2436700T3 (pl) *	2007-03-23	2018-12-31	Wyeth Llc	Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
US8398985B2 (en) *	2007-04-23	2013-03-19	Serum Institute Of India Ltd.	Antigenic polysaccharides and process for their preparation
BRPI0811979A2 (pt) *	2007-06-04	2014-10-21	Novartis Ag	Formulação para vacinas de meningite
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
ES2528648T3 (es) *	2007-09-11	2015-02-11	University Of Guelph	Inmunógenos polisacáridos de la Clostridium Difficile
ATE553774T1 (de)	2007-10-19	2012-05-15	Novartis Ag	Meningokokkenimpfstoffformulierungen
US9579372B2 (en)	2008-02-21	2017-02-28	Glaxosmithkline Biologicals Sa	Meningococcal fHBP polypeptides
CN101724085B (zh) *	2008-10-22	2011-09-21	上海生物制品研究所	一种荚膜多糖纯化方法
SI2349520T1 (sl)	2008-10-27	2016-08-31	Glaxosmithkline Biologicals S.A.	Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
AU2009329193A1 (en)	2008-12-17	2011-07-14	Novartis Ag	Meningococcal vaccines including hemoglobin receptor
EP2470204B1 (fr)	2009-08-27	2015-12-16	GlaxoSmithKline Biologicals SA	Polypeptides hybrides contenant des séquences fhbp à méningocoques
BR112012009014B8 (pt)	2009-09-30	2022-10-04	Novartis Ag	Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
WO2011051893A1 (fr)	2009-10-27	2011-05-05	Novartis Ag	Polypeptides fhbp méningococciques modifiés
WO2011051917A1 (fr)	2009-10-30	2011-05-05	Novartis Ag	Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
WO2012020326A1 (fr)	2010-03-18	2012-02-16	Novartis Ag	Vaccins adjuvantés contre le méningocoque de sérogroupe b
HRP20240965T1 (hr)	2010-08-23	2024-10-25	Wyeth Llc	Stabilne formulacije antigena rlp2086 iz bakterije neisseria meningitidis
ES2744471T3 (es)	2010-09-04	2020-02-25	Glaxosmithkline Biologicals Sa	Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
PE20140173A1 (es)	2010-09-10	2014-02-20	Wyeth Llc	Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
WO2012085668A2 (fr)	2010-12-24	2012-06-28	Novartis Ag	Composés
CN103533954B (zh)	2011-03-02	2015-09-09	诺华股份有限公司	含较低剂量的抗原和/或佐剂的联合疫苗
CN103764171B (zh)	2011-07-08	2016-08-17	诺华股份有限公司	酪氨酸连接方法
CU20110202A7 (es)	2011-11-02	2013-12-27	Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas	Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
WO2013068949A1 (fr)	2011-11-07	2013-05-16	Novartis Ag	Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
CA2863178C (fr) *	2012-01-30	2021-04-06	Serum Institute Of India Ltd.	Composition immunogene
CN104159603A (zh)	2012-03-08	2014-11-19	诺华股份有限公司	带有tlr4激动剂的联合疫苗
SG10201602558UA (en)	2012-03-09	2016-05-30	Pfizer	Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
SG11201407440WA (en)	2012-05-22	2014-12-30	Novartis Ag	Meningococcus serogroup x conjugate
WO2014009971A2 (fr) *	2012-07-07	2014-01-16	Bharat Biotech International Limited	Compositions vaccinales sans alcool excluant toute origine animale et leur procédé de préparation
CN103623404B (zh) *	2012-08-28	2016-08-03	天士力制药集团股份有限公司	一种b型流感嗜血杆菌多糖结合疫苗的制备方法
RU2015106930A (ru)	2012-09-06	2016-10-20	Новартис Аг	Комбинированные вакцины с менингококком серогруппы в и к/д/с
CN104936615B (zh)	2012-11-21	2017-03-29	印度血清研究所私人有限公司	高产量的细菌多糖的制备
CN105007935A (zh)	2012-12-18	2015-10-28	葛兰素史密丝克莱恩生物有限公司	用于保护免于白喉和/或破伤风的缀合物
US9802987B2 (en)	2013-03-08	2017-10-31	Pfizer Inc.	Immunogenic fusion polypeptides
KR20160040556A (ko)	2013-07-11	2016-04-14	노파르티스 아게	미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
JP2016529885A (ja)	2013-07-12	2016-09-29	イー・エム・デイー・ミリポア・コーポレイシヨン	活性炭を使用して標的タンパク質を含む試料からのウイルス除去を決定する方法
WO2015033251A2 (fr)	2013-09-08	2015-03-12	Pfizer Inc.	Compositions utilisables contre neisseria meningitidis et procédés associés
SI3110442T1 (sl)	2014-02-28	2021-01-29	Glaxosmithkline Biologicals S.A.	Modificirani meningokokni fHbp polipeptidi
EP3148577B1 (fr)	2014-05-24	2021-01-20	Biological E Limited	Nouveau vaccin conjugué méningococcique semi-synthétique
CN104548090B (zh) *	2015-01-27	2016-11-30	中国科学院过程工程研究所	一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
MX2017010705A (es)	2015-02-19	2017-12-04	Pfizer	Composiciones de neisseria meningitidis y metodos de la misma.
CN105037579A (zh) *	2015-08-31	2015-11-11	成都欧林生物科技股份有限公司	A群脑膜炎球菌细菌荚膜粗多糖的制备工艺
WO2017175082A1 (fr)	2016-04-05	2017-10-12	Gsk Vaccines S.R.L.	Compositions immunogènes
JP7104027B2 (ja)	2016-09-02	2022-07-20	グラクソスミスクラインバイオロジカルズソシエテアノニム	淋菌に対するワクチン
CN118236477A (zh)	2016-09-02	2024-06-25	赛诺菲巴斯德股份有限公司	脑膜炎奈瑟氏菌疫苗
MX2019007910A (es)	2016-12-30	2019-12-05	Sutrovax Inc	Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US11951165B2 (en)	2016-12-30	2024-04-09	Vaxcyte, Inc.	Conjugated vaccine carrier proteins
SG11201906519RA (en)	2017-01-31	2019-08-27	Pfizer	Neisseria meningitidis compositions and methods thereof
CA3052621A1 (fr)	2017-02-03	2018-08-09	Schadeck, Eva Barbara	Compositions de conjugue saccharide d'haemophilus influenzae-excipient et leurs utilisations
EP3585427A4 (fr) *	2017-02-24	2020-12-30	Merck Sharp & Dohme Corp.	Procédés d'amélioration de la filtrabilité de réactions de polysaccharide conjugué à une protéine
US11400162B2 (en)	2017-02-24	2022-08-02	Merck Sharp & Dohme Llc	Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EA201992636A1 (ru) *	2017-05-05	2020-04-17	Серум Инститьют Оф Индия Прайват Лимитед	Способ удаления примесей из препаратов на основе бактериальных капсулярных полисахаридов
RU2019140392A (ru) *	2017-05-17	2021-06-17	Мсд Веллком Траст Хиллеман Лабораторис Пвт. Лтд.	Очистка бактериальных полисахаридов
CN111050794A (zh) *	2017-09-07	2020-04-21	默沙东公司	将肺炎球菌多糖与载体蛋白缀合的配制方法
WO2019175900A1 (fr) *	2018-03-16	2019-09-19	Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.	Purification de polysaccharides de neisseria meningitidis
BR112021017239A2 (pt) *	2019-03-08	2021-11-09	Glaxosmithkline Biologicals Sa	Derivados carbocíclicos e derivados conjugados dos mesmos, e seu uso em vacinas
CA3139257A1 (fr)	2019-05-10	2020-11-19	Glaxosmithkline Biologicals Sa	Production de conjugues
US20220387614A1 (en)	2019-11-22	2022-12-08	Glaxosmithkline Biologicals Sa	Dosage and administration of a bacterial saccharide glycoconjugate vaccine
GB202013262D0 (en)	2020-08-25	2020-10-07	Glaxosmithkline Biologicals Sa	Vaccine Composition
CN115721709A (zh) *	2021-08-27	2023-03-03	康希诺生物股份公司	一种肺炎球菌结合疫苗制备方法
GB202115151D0 (en)	2021-10-21	2021-12-08	Glaxosmithkline Biologicals Sa	Methods
GB202208089D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition
GB202208093D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB207117A (en)	1923-04-05	1923-11-22	Fernand Prosper Constant Lebru	Improvements in otter boards
US4057685A (en)	1972-02-02	1977-11-08	Abbott Laboratories	Chemically modified endotoxin immunizing agent
US4123520A (en) *	1977-08-01	1978-10-31	Merck & Co., Inc.	Method for preparing high molecular weight meningococcal Group C vaccine
US4134214A (en)	1977-08-05	1979-01-16	Merck & Co., Inc.	Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
DE2748132A1 (de)	1977-10-27	1979-05-03	Behringwerke Ag	Stabilisator fuer polysaccharid
US4220717A (en)	1977-12-22	1980-09-02	American Cyanamid Company	Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4242501A (en) *	1979-08-08	1980-12-30	American Cyanamid Company	Purification of pneumococcal capsular polysaccharides
US4351762A (en)	1981-03-10	1982-09-28	Bioresearch, Inc.	Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en)	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
BE889979A (fr) *	1981-08-14	1982-02-15	Smith Kline Rit	Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4673574A (en)	1981-08-31	1987-06-16	Anderson Porter W	Immunogenic conjugates
US4902506A (en)	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
US4451446A (en) *	1982-03-04	1984-05-29	Smithkline-Rit	Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4496538A (en)	1982-07-06	1985-01-29	Connaught Laboratories, Inc.	Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
JPS59176214A (ja) *	1982-11-23	1984-10-05	ザ・ウエルカム・フアウンデ−シヨン・リミテツド	抗原性組成物
EP0109688A3 (fr)	1982-11-23	1986-12-03	The Wellcome Foundation Limited	Complexes, procédés pour leur obtention et formulations contenant de tels complexes
US4459286A (en)	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
US4663160A (en)	1983-03-14	1987-05-05	Miles Laboratories, Inc.	Vaccines for gram-negative bacteria
US4761283A (en)	1983-07-05	1988-08-02	The University Of Rochester	Immunogenic conjugates
US4762713A (en)	1983-07-05	1988-08-09	The University Of Rochester	Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
EP0145359B1 (fr) *	1983-11-21	1991-01-16	The Wellcome Foundation Limited	Complexes, leur procédé de préparation et formulations les contenant
US4695624A (en)	1984-05-10	1987-09-22	Merck & Co., Inc.	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en)	1984-05-10	1989-11-21	Merck & Co., Inc.	Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en)	1984-07-09	1989-02-28	Praxis Biologics, Inc.	Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it)	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
US4814276A (en)	1986-04-25	1989-03-21	Becton, Dickinson And Company	Selective medium for growth of neisseria
US4877613A (en)	1987-08-05	1989-10-31	Biotech Connections, Inc.	Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli
US4761713A (en) *	1987-11-06	1988-08-02	North American Philips Corp.	Glycol based mid-volt capacitor
GB8815795D0 (en)	1988-07-02	1988-08-10	Bkl Extrusions Ltd	Glazing bead
NL8802046A (nl)	1988-08-18	1990-03-16	Gen Electric	Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de)	1988-12-07	1990-06-13	Behringwerke Ag	Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
WO1990006696A2 (fr)	1988-12-19	1990-06-28	Praxis Biologics, Inc.	Vaccin meningocoque de la proteine de la membrane externe de la classe 1
ES2055785T3 (es)	1989-01-17	1994-09-01	Eniricerche Spa	Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US4963534A (en)	1989-05-19	1990-10-16	Merck & Co., Inc.	Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
CA2017507C (fr)	1989-05-25	1996-11-12	Gary Van Nest	Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
US5334379A (en)	1989-07-14	1994-08-02	American Cyanamid Company	Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
HU9201966D0 (en) *	1989-12-14	1992-10-28	Ca Nat Research Council	An improved vaccine of meningococcus-polysaccharide conjunction
DE69113564T2 (de)	1990-08-13	1996-05-30	American Cyanamid Co	Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5256294A (en) *	1990-09-17	1993-10-26	Genentech, Inc.	Tangential flow filtration process and apparatus
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
CA2059693C (fr) *	1991-01-28	2003-08-19	Peter J. Kniskern	Antigenes polysaccharides de streptococcus pneumoniae
CA2059692C (fr) *	1991-01-28	2004-11-16	Peter J. Kniskern	Vaccin conjugue de polysaccharide contre les pneumocoques
JP2631035B2 (ja)	1991-03-12	1997-07-16	アメリカ合衆国	多糖類−タンパク質複合体
US5314811A (en)	1992-07-13	1994-05-24	Merck & Co., Inc.	Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
WO1993004183A1 (fr) *	1991-08-16	1993-03-04	Merck & Co., Inc.	Procede de conversion d'un polysaccharide capsulaire bacterien contenant des lipides en polysaccharide sans lipide
FR2682388B1 (fr)	1991-10-10	1995-06-09	Pasteur Merieux Serums Vacc	Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
DE69333110T2 (de)	1992-03-02	2004-05-06	Chiron S.P.A.	Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
IT1262896B (it)	1992-03-06	1996-07-22		Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DE69334297D1 (de)	1992-05-23	2009-11-12	Glaxosmithkline Biolog Sa	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
ATE188613T1 (de)	1992-06-25	2000-01-15	Smithkline Beecham Biolog	Adjuvantien enthaltende impfstoffzusammensetzung
IL102687A (en)	1992-07-30	1997-06-10	Yeda Res & Dev	Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
ATE254475T1 (de) *	1993-09-22	2003-12-15	Jackson H M Found Military Med	Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
AU696941B2 (en)	1994-07-01	1998-09-24	Rican Limited	Helicobacter pylori antigenic protein preparation and immunoassays
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
ATE328890T1 (de)	1994-07-15	2006-06-15	Univ Iowa Res Found	Immunomodulatorische oligonukleotide
GB9422096D0 (en)	1994-11-02	1994-12-21	Biocine Spa	Combined meningitis vaccine
US6696065B1 (en) *	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
PT1090642E (pt)	1995-06-07	2008-09-09	Glaxosmithkline Biolog Sa	Vacinas compreendendo um conjugado de antigénio polissacarídico - proteína veículo e proteína veículo livre
US5811102A (en)	1995-06-07	1998-09-22	National Research Council Of Canada	Modified meningococcal polysaccharide conjugate vaccines
US20030157129A1 (en)	1995-06-23	2003-08-21	Smithkline Beecham Biologicals S.A.	Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
SI0833662T2 (sl) *	1995-06-23	2011-06-30	Smithkline Beecham Biolog	Cepivni sestavek, ki vsebuje polisaharidni konjugirani antigen haemophilus influenzae b adsorbiran na aluminijevem fosfatu
US20020054884A1 (en)	1995-06-23	2002-05-09	Smithkline Beecham Biologicals, Sa	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9513261D0 (en)	1995-06-29	1995-09-06	Smithkline Beecham Biolog	Vaccines
DE69737413T2 (de)	1996-01-04	2007-10-31	Novartis Vaccines and Diagnostics, Inc., Emeryville	Bakterioferritin aus helicobacter pylori
JP2001508758A (ja)	1996-02-01	2001-07-03	ノース・アメリカン・バクシーン・インコーポレイテッド	グループｂナイセリア・メニンギチジス外膜（ｍｂ３）タンパク質の酵母からの発現およびワクチン
EP0897427B1 (fr) †	1996-02-14	2004-10-27	Merck & Co., Inc.	Procede de precipitation de polysaccharides
DE19630390A1 (de)	1996-07-26	1998-01-29	Chiron Behring Gmbh & Co	Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
CA2264735C (fr) *	1996-08-27	2008-01-29	Chiron Corporation	Glycoconjugues du groupe serologique b de neisseria meningitidis et leurs procedes d'utilisation
EP0930893B1 (fr)	1996-10-11	2005-04-13	The Regents of The University of California	Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6248334B1 (en)	1997-01-08	2001-06-19	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
AU722315B2 (en)	1997-01-21	2000-07-27	Pasteur Merieux Serums Et Vaccins	Polysaccharide-peptide conjugates
DE59812033D1 (de) *	1997-01-24	2004-11-04	Schweiz Serum & Impfinst	Neues verfahren zur isolierung von polysacchariden
EP1039935A4 (fr)	1997-02-28	2005-04-27	Univ Iowa Res Found	UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
WO1998040100A1 (fr)	1997-03-10	1998-09-17	Ottawa Civic Loeb Research Institute	UTILISATION D'ACIDES NUCLEIQUES CONTENANT UN DINUCLEOTIDE CpG NON METHYLE EN TANT QU'ADJUVANT
US6299881B1 (en)	1997-03-24	2001-10-09	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6403306B1 (en)	1997-04-09	2002-06-11	Emory University	Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
JP2002504096A (ja)	1997-04-24	2002-02-05	ヘンリーエム．ジャクソンファウンデーションフォーザアドバンスメントオブミリタリーメディシン	タンパク質−多糖ワクチンの調製のための未修飾タンパク質とハロアシルまたはジハロアシル誘導体化された多糖との結合
WO1998052581A1 (fr)	1997-05-20	1998-11-26	Ottawa Civic Hospital Loeb Research Institute	Vecteurs et procedes destines a l'immunisation et a des protocoles therapeutiques
JP4173560B2 (ja)	1997-05-28	2008-10-29	カイロンソチエタアレスポンサビリタリミタータ	アミノ酸源として酵母または大豆抽出物を含み、動物起源のタンパク質複合体を含まない培養培地
DE69840850D1 (de)	1997-06-06	2009-07-09	Dynavax Tech Corp	Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en)	1997-06-14	1997-08-13	Smithkline Beecham Biolog	Vaccine
GB9713156D0 (en)	1997-06-20	1997-08-27	Microbiological Res Authority	Vaccines
US6413520B1 (en)	1997-06-24	2002-07-02	Chiron Corporation	Methods of immunizing adults using anti-meningococcal vaccine compositions
US6030619A (en) *	1997-08-27	2000-02-29	Chiron Corporation	Molecular mimetics of meningococcal B epitopes
DE69815692T2 (de)	1997-09-05	2004-04-29	Glaxosmithkline Biologicals S.A.	Öl in wasser emulsionen mit saponinen
US5965714A (en)	1997-10-02	1999-10-12	Connaught Laboratories, Inc.	Method for the covalent attachment of polysaccharides to protein molecules
ATE476508T1 (de)	1997-11-06	2010-08-15	Novartis Vaccines & Diagnostic	Neisseriale antigene
WO1999027105A2 (fr)	1997-11-21	1999-06-03	Genset	Sequence genomique et polypeptides de chlamydia pneumoniae, leurs fragments et leurs utilisations, en particulier pour le diagnostic, la prevention ou le traitement d'une infection
GB9725084D0 (en)	1997-11-28	1998-01-28	Medeva Europ Ltd	Vaccine compositions
CA2309228A1 (fr)	1997-11-28	1999-06-10	Genset S.A.	Sequence genomique et polypeptides de chlamydia trachomatis, leurs fragments et leurs utilisations, en particulier, pour le diagnostic, la prevention et le traitement de l'infection
DE69841676D1 (de)	1997-12-23	2010-07-01	Baxter Healthcare Sa	Verfahren zur extraktion und isolierung von bakteriellen hüllpolysacchariden zur verwendung als vakzine oder, an proteine gekoppelt, als konjugierte vakzine
BR9906927A (pt)	1998-01-14	2001-11-20	Chiron Spa	Proteìnas de neisseria meningitidis
US7018637B2 (en) *	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en)	1998-03-05	2001-10-16	The Medical College Of Ohio	IL-12 enhancement of immune responses to T-independent antigens
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
IL138000A0 (en)	1998-04-09	2001-10-31	Smithkline Beecham Biolog	Adjuvant compositions
BR9910089A (pt)	1998-05-01	2004-06-08	Chiron Corp	Composições e antìgenos de neisseria meningitidis
US8007815B1 (en) †	1998-05-29	2011-08-30	Novartis Ag	Combination meningitidis B/C vaccines
GB9817052D0 (en)	1998-08-05	1998-09-30	Smithkline Beecham Biolog	Vaccine
KR100704826B1 (ko)	1998-08-19	2007-04-09	박스터 헬쓰케어 에스.에이.	Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
US6128656A (en) *	1998-09-10	2000-10-03	Cisco Technology, Inc.	System for updating selected part of configuration information stored in a memory of a network element depending on status of received state variable
MXPA01003557A (es)	1998-10-09	2004-04-05	Chiron Corp	Secuencias genomicas de neisseria y metodos para su uso.
CN100558401C (zh)	1998-10-16	2009-11-11	史密丝克莱恩比彻姆生物有限公司	佐剂系统及疫苗
EP1133572A4 (fr)	1998-11-12	2005-06-15	Univ California	Sequence genomique de chlamydia pneumoniae
GB9828000D0 (en)	1998-12-18	1999-02-10	Chiron Spa	Antigens
US6146902A (en)	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
JP4846906B2 (ja) *	1999-03-19	2011-12-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
FR2791895B1 (fr)	1999-03-23	2001-06-15	Pasteur Merieux Serums Vacc	Utilisation de trehalose pour stabiliser un vaccin liquide
WO2000061761A2 (fr)	1999-04-09	2000-10-19	Techlab, Inc.	Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
IL145982A0 (en)	1999-04-19	2002-07-25	Smithkline Beecham Biolog	Vaccines
WO2000071725A2 (fr)	1999-05-19	2000-11-30	Chiron S.P.A.	Compositions a base de combinaisons de neisseria
GB9918319D0 (en) *	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US6531131B1 (en)	1999-08-10	2003-03-11	The United States Of America As Represented By The Department Of Health And Human Services	Conjugate vaccine for Neisseria meningitidis
BR0014285A (pt)	1999-09-24	2002-05-21	Smithkline Beecham Biolog	Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
CZ20021043A3 (cs)	1999-09-24	2002-08-14	Smithkline Beecham Biologicals S. A.	Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
GB9925559D0 (en)	1999-10-28	1999-12-29	Smithkline Beecham Biolog	Novel method
DE60039450D1 (de) *	1999-12-02	2008-08-21	Novartis Vaccines & Diagnostic	Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
DK1248647T3 (da)	2000-01-17	2010-09-27	Novartis Vaccines & Diagnostic	Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
RU2299906C2 (ru)	2000-02-28	2007-05-27	Новартис Вэксинс Энд Диагностикс С.Р.Л.	Гетерологичная экспрессия белков neisseria
US6800455B2 (en)	2000-03-31	2004-10-05	Scios Inc.	Secreted factors
ES2385100T3 (es)	2000-06-29	2012-07-18	Smithkline Beecham Biologicals S.A.	Composición de vacuna multivalente con dosis reducida de Haemophilus influenzae de tipo B
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
ATE440861T1 (de)	2000-07-03	2009-09-15	Novartis Vaccines & Diagnostic	Immunisierung gegen chlamydia pneumoniae
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
US6753015B2 (en) *	2000-09-28	2004-06-22	Chiron Corporation	Microparticle compositions and methods for the manufacture thereof
AU1412702A (en)	2000-10-27	2002-05-06	Chiron Spa	Nucleic acids and proteins from streptococcus groups a and b
AP1897A (en)	2001-01-23	2008-10-10	Aventis Pasteur	Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
CA2439111A1 (fr) *	2001-04-05	2002-10-17	Chiron Corporation	Augmentation de l'immunite des muqueuses a la suite d'un amorcage parenteral
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
WO2003028661A2 (fr)	2001-10-03	2003-04-10	Chiron Corporation	Compositions de meningocoque assorties d'un adjuvant
ES2318117T3 (es)	2002-03-26	2009-05-01	Novartis Vaccines And Diagnostics S.R.L.	Sacaridos modificados que tienen una estabilidad mejorada en agua.
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
MXPA04011248A (es)	2002-05-14	2005-02-17	Chiron Srl	Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0220198D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Modified saccharides,conjugates thereof and their manufacture
PT2353608T (pt)	2002-10-11	2020-03-11	Novartis Vaccines And Diagnostics S R L	Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
US10272147B2 (en)	2003-01-30	2019-04-30	Glaxosmithkline Biologicals S.A.	Injectable vaccines against multiple meningococcal serogroups
GB0409745D0 (en) *	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
EP2357001B1 (fr)	2006-03-22	2018-03-07	GlaxoSmithKline Biologicals S.A.	Schema posologique pour une immunisation avec des conjugues de meningocoques
GB0822633D0 (en) *	2008-12-11	2009-01-21	Novartis Ag	Formulation
GB2495341B (en) *	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products

2001
- 2001-06-20 GB GBGB0115176.0A patent/GB0115176D0/en not_active Ceased
2002
- 2002-06-20 CA CA2450203A patent/CA2450203C/fr not_active Expired - Lifetime
- 2002-06-20 EP EP02755452.6A patent/EP1401489B2/fr not_active Expired - Lifetime
- 2002-06-20 ES ES09075005.0T patent/ES2603275T3/es not_active Expired - Lifetime
- 2002-06-20 DE DE122011000003C patent/DE122011000003I1/de active Pending
- 2002-06-20 JP JP2003513590A patent/JP5075317B2/ja not_active Expired - Lifetime
- 2002-06-20 DE DE122010000040C patent/DE122010000040I1/de active Pending
- 2002-06-20 ES ES09075009.2T patent/ES2670196T3/es not_active Expired - Lifetime
- 2002-06-20 DK DK10007477.2T patent/DK2263688T4/da active
- 2002-06-20 ES ES06075175T patent/ES2347458T3/es not_active Expired - Lifetime
- 2002-06-20 CN CNB028124448A patent/CN100482273C/zh not_active Expired - Lifetime
- 2002-06-20 ES ES02755452T patent/ES2261705T5/es not_active Expired - Lifetime
- 2002-06-20 EP EP10179806.4A patent/EP2277537B1/fr not_active Expired - Lifetime
- 2002-06-20 PT PT02755452T patent/PT1401489E/pt unknown
- 2002-06-20 AU AU2002321716A patent/AU2002321716B2/en not_active Expired
- 2002-06-20 PT PT101798064T patent/PT2277537E/pt unknown
- 2002-06-20 DE DE122010000042C patent/DE122010000042I1/de active Pending
- 2002-06-20 CN CNA2009101281393A patent/CN101524533A/zh active Pending
- 2002-06-20 DE DE60210456T patent/DE60210456T3/de not_active Expired - Lifetime
- 2002-06-20 DK DK09075005.0T patent/DK2184071T3/en active
- 2002-06-20 EP EP09075009.2A patent/EP2216044B1/fr not_active Expired - Lifetime
- 2002-06-20 NZ NZ529881A patent/NZ529881A/xx not_active IP Right Cessation
- 2002-06-20 ES ES09075006.8T patent/ES2573259T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP10179797.5A patent/EP2277536B1/fr not_active Expired - Lifetime
- 2002-06-20 EP EP10180707A patent/EP2277539A3/fr not_active Ceased
- 2002-06-20 RU RU2004101284/13A patent/RU2381814C2/ru not_active Application Discontinuation
- 2002-06-20 CN CN200910128140.6A patent/CN101524534B/zh not_active Expired - Lifetime
- 2002-06-20 PT PT101797975T patent/PT2277536T/pt unknown
- 2002-06-20 DE DE122010000041C patent/DE122010000041I1/de active Pending
- 2002-06-20 EP EP06075175A patent/EP1741442B1/fr not_active Expired - Lifetime
- 2002-06-20 WO PCT/IB2002/003191 patent/WO2003007985A2/fr active IP Right Grant
- 2002-06-20 TR TR2018/08026T patent/TR201808026T4/tr unknown
- 2002-06-20 US US10/481,457 patent/US8753651B2/en active Active
- 2002-06-20 AT AT06075175T patent/ATE474594T1/de active
- 2002-06-20 DK DK02755452.6T patent/DK1401489T4/da active
- 2002-06-20 PT PT10007477T patent/PT2263688E/pt unknown
- 2002-06-20 CN CN200910128141.0A patent/CN101524535B/zh not_active Expired - Lifetime
- 2002-06-20 ES ES10007477T patent/ES2387592T5/es not_active Expired - Lifetime
- 2002-06-20 DK DK09075006.8T patent/DK2189165T3/en active
- 2002-06-20 MX MXPA03011462A patent/MXPA03011462A/es active IP Right Grant
- 2002-06-20 DK DK10179797.5T patent/DK2277536T3/en active
- 2002-06-20 EP EP09075006.8A patent/EP2189165B1/fr not_active Expired - Lifetime
- 2002-06-20 AT AT02755452T patent/ATE322287T1/de active
- 2002-06-20 ES ES10179797.5T patent/ES2662015T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP10007477.2A patent/EP2263688B2/fr not_active Expired - Lifetime
- 2002-06-20 DK DK06075175.7T patent/DK1741442T3/da active
- 2002-06-20 AT AT10007477T patent/ATE556718T1/de active
- 2002-06-20 EP EP09075005.0A patent/EP2184071B1/fr not_active Expired - Lifetime
- 2002-06-20 EP EP09075010.0A patent/EP2229954B1/fr not_active Expired - Lifetime
- 2002-06-20 ES ES09075010.0T patent/ES2670219T3/es not_active Expired - Lifetime
- 2002-06-20 BR BRPI0210590-0 patent/BRPI0210590B8/pt not_active IP Right Cessation
- 2002-06-20 BR BR122019009186A patent/BR122019009186B8/pt not_active IP Right Cessation
- 2002-06-20 TR TR2018/08055T patent/TR201808055T4/tr unknown
- 2002-06-20 CA CA2730856A patent/CA2730856C/fr not_active Expired - Lifetime
- 2002-06-20 NZ NZ544332A patent/NZ544332A/en not_active IP Right Cessation
- 2002-06-20 CA CA2641585A patent/CA2641585C/fr not_active Expired - Lifetime
- 2002-06-20 PT PT06075175T patent/PT1741442E/pt unknown
- 2002-06-20 ES ES10179806.4T patent/ES2539134T3/es not_active Expired - Lifetime
- 2002-06-20 DE DE60237123T patent/DE60237123D1/de not_active Expired - Lifetime
- 2002-06-20 PT PT90750050T patent/PT2184071T/pt unknown
2007
- 2007-07-24 AU AU2007203442A patent/AU2007203442B2/en not_active Expired
2009
- 2009-01-09 US US12/351,281 patent/US8889152B2/en not_active Expired - Lifetime
- 2009-01-14 US US12/353,409 patent/US8852606B2/en active Active
- 2009-01-20 US US12/321,464 patent/US9358278B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,434 patent/US9782467B2/en not_active Expired - Lifetime
- 2009-01-20 US US12/321,417 patent/US9452207B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,420 patent/US20090130147A1/en not_active Abandoned
- 2009-01-20 US US12/321,418 patent/US9782466B2/en not_active Expired - Lifetime
- 2009-02-26 JP JP2009044925A patent/JP5380111B2/ja not_active Expired - Lifetime
- 2009-02-26 JP JP2009044924A patent/JP5220658B2/ja not_active Expired - Lifetime
- 2009-03-11 RU RU2009108660/10A patent/RU2528066C2/ru active
2010
- 2010-09-13 FR FR10C0044C patent/FR10C0044I1/fr active Active
- 2010-09-13 NL NL300458C patent/NL300458I2/nl unknown
- 2010-09-13 BE BE2010C031C patent/BE2010C031I2/fr unknown
- 2010-09-13 BE BE2010C033C patent/BE2010C033I2/fr unknown
- 2010-09-13 BE BE2010C032C patent/BE2010C032I2/fr unknown
- 2010-09-13 NL NL300459C patent/NL300459I2/nl unknown
- 2010-09-13 FR FR10C0043C patent/FR10C0043I1/fr active Active
- 2010-09-13 NL NL300460C patent/NL300460I2/nl unknown
- 2010-09-13 FR FR10C0042C patent/FR10C0042I1/fr active Active
- 2010-09-14 LU LU91734C patent/LU91734I2/fr unknown
- 2010-09-14 LU LU91733C patent/LU91733I2/fr unknown
- 2010-09-14 LU LU91732C patent/LU91732I2/fr unknown
- 2010-10-11 CY CY20101100902T patent/CY1110820T1/el unknown
- 2010-11-19 AU AU2010246331A patent/AU2010246331B2/en not_active Expired
2011
- 2011-01-13 BE BE2011C001C patent/BE2011C001I2/fr unknown
- 2011-01-13 LU LU91778C patent/LU91778I2/fr unknown
- 2011-01-14 FR FR11C0001C patent/FR11C0001I2/fr active Active
- 2011-01-18 CY CY2011001C patent/CY2011001I2/el unknown
2012
- 2012-08-03 CY CY20121100693T patent/CY1113020T1/el unknown
- 2012-10-05 JP JP2012222942A patent/JP2013007057A/ja not_active Withdrawn
2016
- 2016-05-18 CY CY20161100432T patent/CY1117528T1/el unknown
- 2016-10-21 CY CY20161101065T patent/CY1118130T1/el unknown
- 2016-10-31 US US15/339,741 patent/US10716841B2/en not_active Expired - Fee Related
2018
- 2018-03-30 CY CY20181100356T patent/CY1120499T1/el unknown

Also Published As

Publication number	Publication date
PT1401489E (pt)	2006-08-31
US20090181053A1 (en)	2009-07-16
ES2387592T3 (es)	2012-09-26
NZ529881A (en)	2006-03-31
LU91733I9 (fr)	2019-01-07
TR201808026T4 (tr)	2018-06-21
EP1401489B2 (fr)	2013-04-10
FR10C0042I1 (fr)	2010-10-29
LU91778I2 (fr)	2011-03-14
EP2189165A1 (fr)	2010-05-26
US20090181049A1 (en)	2009-07-16
ATE556718T1 (de)	2012-05-15
TR201808055T4 (tr)	2018-06-21
DE60210456T3 (de)	2013-09-05
EP2277536A2 (fr)	2011-01-26
BR0210590A (pt)	2004-11-09
AU2007203442B2 (en)	2010-08-26
BRPI0210590B1 (pt)	2019-10-01
ES2670219T3 (es)	2018-05-29
EP2263688A1 (fr)	2010-12-22
CN101524535B (zh)	2015-12-16
CY1110820T1 (el)	2012-01-25
JP2009114211A (ja)	2009-05-28
CA2730856A1 (fr)	2003-01-30
CN101524534A (zh)	2009-09-09
AU2010246331B2 (en)	2012-11-08
BR122019009186B1 (pt)	2020-05-26
EP1401489B1 (fr)	2006-04-05
ES2539134T3 (es)	2015-06-26
CN101524533A (zh)	2009-09-09
WO2003007985A2 (fr)	2003-01-30
DE122010000040I1 (de)	2010-12-16
DK1401489T4 (da)	2013-07-01
US20090130140A1 (en)	2009-05-21
RU2009108660A (ru)	2010-09-20
DK2277536T3 (en)	2018-02-26
CA2730856C (fr)	2015-07-28
PT2184071T (pt)	2016-11-14
ATE322287T1 (de)	2006-04-15
CA2450203C (fr)	2011-04-19
DK2189165T3 (en)	2016-06-13
EP1741442A2 (fr)	2007-01-10
FR11C0001I2 (fr)	2017-05-19
US9358278B2 (en)	2016-06-07
LU91734I2 (fr)	2011-03-14
CN100482273C (zh)	2009-04-29
RU2004101284A (ru)	2005-06-27
EP1401489A2 (fr)	2004-03-31
EP2229954B1 (fr)	2018-03-21
BE2010C033I2 (fr)	2021-07-19
CA2641585A1 (fr)	2003-01-30
BE2010C032I2 (fr)	2021-07-19
US8852606B2 (en)	2014-10-07
US9782467B2 (en)	2017-10-10
CN101524534B (zh)	2014-05-28
EP2216044B1 (fr)	2018-03-21
US20090117148A1 (en)	2009-05-07
ES2347458T3 (es)	2010-10-29
US20090182129A1 (en)	2009-07-16
LU91733I2 (fr)	2011-03-14
CY1118130T1 (el)	2017-06-28
DE122011000003I1 (de)	2011-05-05
RU2381814C2 (ru)	2010-02-20
US20090182128A1 (en)	2009-07-16
LU91732I2 (fr)	2011-03-14
EP2277536B1 (fr)	2018-01-31
CA2450203A1 (fr)	2003-01-30
US20170043004A1 (en)	2017-02-16
EP2229954A1 (fr)	2010-09-22
US10716841B2 (en)	2020-07-21
US8889152B2 (en)	2014-11-18
JP2009114210A (ja)	2009-05-28
DK1401489T3 (da)	2006-07-03
EP2277536A3 (fr)	2011-02-23
CY2011001I1 (el)	2012-01-25
EP2277539A2 (fr)	2011-01-26
ES2261705T3 (es)	2006-11-16
EP1741442B1 (fr)	2010-07-21
DE60210456D1 (de)	2006-05-18
US8753651B2 (en)	2014-06-17
JP5220658B2 (ja)	2013-06-26
BR122019009186B8 (pt)	2021-07-27
JP2004536859A (ja)	2004-12-09
PT2277536T (pt)	2018-03-21
NL300460I2 (fr)	2016-12-20
AU2010246331A1 (en)	2010-12-09
AU2002321716B2 (en)	2007-04-26
GB0115176D0 (en)	2001-08-15
CY1117528T1 (el)	2017-04-26
CY1120499T1 (el)	2019-07-10
PT2263688E (pt)	2012-08-02
DE60237123D1 (de)	2010-09-02
BE2011C001I2 (fr)	2021-07-19
DE122010000041I1 (de)	2010-12-16
JP5075317B2 (ja)	2012-11-21
JP2013007057A (ja)	2013-01-10
DK1741442T3 (da)	2010-08-30
NZ544332A (en)	2006-10-27
WO2003007985A3 (fr)	2003-12-24
NL300459I2 (fr)	2016-12-20
ES2573259T3 (es)	2016-06-06
BRPI0210590B8 (pt)	2021-05-25
MXPA03011462A (es)	2005-04-19
EP2184071A1 (fr)	2010-05-12
FR10C0044I1 (fr)	2010-10-29
LU91732I9 (fr)	2019-01-07
EP2277537A3 (fr)	2011-03-02
US20050106181A1 (en)	2005-05-19
DE122010000042I1 (de)	2010-12-16
AU2007203442A1 (en)	2007-08-16
CY2011001I2 (el)	2012-01-25
EP2216044A1 (fr)	2010-08-11
ES2603275T3 (es)	2017-02-24
CN101524535A (zh)	2009-09-09
US20090130147A1 (en)	2009-05-21
RU2528066C2 (ru)	2014-09-10
EP2263688B2 (fr)	2019-12-25
EP2184071B1 (fr)	2016-08-31
EP2277539A3 (fr)	2011-03-02
CY1113020T1 (el)	2016-04-13
DK2184071T3 (en)	2016-11-07
ES2387592T5 (es)	2020-07-30
FR11C0001I1 (fr)	2011-02-25
ES2261705T5 (es)	2013-07-22
ES2670196T3 (es)	2018-05-29
ATE474594T1 (de)	2010-08-15
CN1518456A (zh)	2004-08-04
ES2662015T3 (es)	2018-04-05
DK2263688T4 (da)	2020-03-02
NL300458I2 (fr)	2016-12-20
EP2263688B1 (fr)	2012-05-09
DK2263688T3 (da)	2012-07-30
LU91734I9 (fr)	2019-01-07
EP1741442A3 (fr)	2007-01-17
LU91778I9 (fr)	2019-01-07
CA2641585C (fr)	2011-02-08
US9782466B2 (en)	2017-10-10
EP2277537B1 (fr)	2015-03-25
DE60210456T2 (de)	2006-11-16
US9452207B2 (en)	2016-09-27
JP5380111B2 (ja)	2014-01-08
EP2277537A2 (fr)	2011-01-26
EP2189165B1 (fr)	2016-03-09
FR10C0043I1 (fr)	2010-10-29
PT1741442E (pt)	2010-10-28
PT2277537E (pt)	2015-06-30

Publication	Publication Date	Title
FR11C0001I1 (fr)	2011-02-25
ZA200306176B (en)	2005-03-30	Multivalent meningococcal polysaccharide-protein conjugate vaccine.
AU2002309706A1 (en)	2002-11-25	Novel meningitis conjugate vaccine
BR9814483A (pt)	2000-10-10	"vacina"
AU2002353417A1 (en)	2003-06-17	Adjuvanted antigenic meningococcal compositions
WO2000025814A3 (fr)	2000-07-27	Constituant pour un vaccin
AU2002342949A1 (en)	2003-06-19	Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
AU2002315309A1 (en)	2002-11-05	Vaccine against tuberculosis
AU2001281828A1 (en)	2002-11-18	Disubstituted 1,7-guanines
AU2002321781A1 (en)	2003-03-24	Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses